



Government **B**ioscience **G**rants

UPDATED MONTHLY

May 12, 2020

—  
THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding


PUBLISHED BY



## Questions?

Liz Powell, Esq., MPH  
lpowell@G2Gconsulting.com

 [www.G2Gconsulting.com](http://www.G2Gconsulting.com)

 [@G2Gconsulting](https://twitter.com/G2Gconsulting)





GOVERNMENT BIOSCIENCE GRANTS

[www.G2Gconsulting.com/bioscience-corner](http://www.G2Gconsulting.com/bioscience-corner)

## GBG Report

**Updated Monthly**

May 12, 2020

Join us for G2G’s GBG Report Highlights call on May 15, 2020 from 10:00AM – 10:30AM by dialing in at (202) 827-6334. Click [here](#) to register. Registration is not required but appreciated.

G2G has been offering a series of webinars on Coronavirus Response Funding and Legislation. Click [here](#) to explore upcoming webinars and to register. Coronavirus funding opportunities are listed in the Report below.

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>ADDICTION/SUBSTANCE ABUSE (4)</b>			
1.	HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Reduce Stigma in Pain Management and Opioid Use Disorder (OUD) and Treatment (NIH)	NOT-TR-20-101  PA-18-591	This Notice of Special Interest (NOSI) calls for research on stigma in the context of chronic pain management and opioid use or opioid use disorder (OUD). As part of NIH’s Helping to End Addiction Long Term (HEAL) Initiative, NIH will support supplements to current HEAL awards to address the challenges for people affected by the opioid crisis from stigma, discrimination and prejudice related to chronic pain management in the context of opioid use and/or opioid use disorder and its treatment. This NOSI calls for applications that integrate and incorporate stigma research into ongoing HEAL funded chronic pain and OUD studies in order to address stigma that is occurring in the context of chronic pain and/or OUD. Because stigma research may require large clinical or community networks, the supplement program is designed to leverage the many networks already being developed through HEAL awards. This supplement program is not intended to support research on basic processes (e.g. cultural attitudes) but rather to result in strategies to enable rapid implementation of changes.	Proposal Due: 5/29/20	Dependent on proposal, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-101.html">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-101.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-591.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-591.html#_Section_II._Award_1</a>

2.	Pre-Announcement Collaborative Partnership between on Alcohol Research Centers and Institutions serving Underserved Communities and Populations (U54 Clinical Trial Optional) (NIH)	NOT-AA-20-006	<p style="text-align: center;"><b>ADDICTION/SUBSTANCE ABUSE</b></p> <p>The National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to publish a FOA inviting Specialized Center Cooperative Agreement (U54) applications for the implementation of collaborative partnership awards between institutions serving underserved communities and populations (IUCP) and other institutions with extensive alcohol research programs, including NIAAA-funded alcohol research centers(ARC). This Notice is being provided to allow potential applicants sufficient time to develop responsive projects. The FOA will utilize the U54 activity code, which provides a mechanism for fostering a mutually beneficial collaboration between IUCP and ARC. This FOA is expected to be published in the spring of 2020 with an expected application due date in the Fall 2020.</p>	<p>Estimated Post Date: 5/1/20</p> <p>Estimated Proposal Due Date: 10/7/20</p>	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326709">https://www.grants.gov/web/grants/view-opportunity.html?opId=326709</a>
3.	Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed) (NIH)	PAR-20-182	<p>This FOA aims to support research that employs innovative scalable technologies to identify, map, and profile cellular ensembles and/or cell-types that produce and/or respond to opioids or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on approaches that enable high-throughput single-cell resolution mapping, anatomical characterization and/or molecular profiling of cells identified as targets of, or as primary sources of opioids in the brain.</p>	<p>Letter of Intent Due: 9/30/20</p> <p>Proposal Due: 10/30/20</p>	Up to \$1 million per year, for up to 5 year	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-182.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-182.html#_Section_II_Award_1</a>

4.	Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience (NIH)	NOT-DA-20-022 PAR-19-368 PAR-19-054 PAR-19-053 PAR-019-093 PAR-019-056 PAR-019-055 PAR-019-091	<p style="text-align: center;"><b>ADDICTION/SUBSTANCE ABUSE</b></p> <p>This Notice invites cutting edge computational approaches to utilize substance use disorder (SUD) data to its full potential and provide powerful insights into the etiology, prevention, and treatment of SUD. Research using basic or clinical approaches is appropriate. NIDA seeks applications combining computational and experimental methodologies towards understanding neurobiological mechanisms related to SUD prevention and treatment. Applications may rely on existing data or propose to collect new data towards development and validation of models. Projects are encouraged to include close collaboration between quantitative and experimental researchers with expertise in HIV/AIDS SUD neuroscience, including scientists from statistics, physics, mathematics, engineering, and computer science. Investigators are encouraged to make the data generated from these projects findable, accessible, interoperable, and reusable (FAIR) to enable secondary analysis by the research community. Similarly, investigators are encouraged to make any computational tools developed through these projects widely available to the neuroscience research community for their use and modification.</p> <p>Topics of interest include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Identifying neurosignatures for disease progression and therapy effectiveness using artificial intelligence (AI)-based tools</li> <li>• Applying computational tools to neurobehavioral data towards predicting efficacy of device-based SUD treatment</li> <li>• Applying simulation-based approaches towards understanding whole brain dynamics related to SUD</li> <li>• Identifying potential subtypes within SUD patient populations by AI-based tools to behavioral, neuroimaging, and clinical measures</li> <li>• Using computational tools to identify molecular biomarkers representing disruption in host immune and defense mechanisms, host genetic determinants, and cellular or brain circuitry neurosignatures relevant to neuroHIV in the context of substance use or SUD.</li> </ul>	Dependent upon Proposal	Dependent upon Proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-022.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-022.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-368.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/PA-19-368.html#_SectionII_Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-054.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/PA-19-054.html#_SectionII_Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-092.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/PA-19-092.html#_SectionII_Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-056.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/PA-19-056.html#_SectionII_Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-055.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/PA-19-055.html#_SectionII_Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-091.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/PA-19-091.html#_SectionII_Award1</a>
----	---	---	---	-------------------------	-------------------------	---

<b>BROAD AGENCY ANNOUNCEMENTS (20)</b>						
5.	BARDA Broad Agency Announcement (HHS)	BAA-18-100-SOL-00003	The BARDA Broad Agency Announcement will not allow submissions of white papers or full proposals for any of the research areas of interest until further notice. Due to our response to the SARS-CoV-2 virus and the necessity to prioritize resources, only submissions to special instructions for efforts that directly support our response to SARS-CoV-2 or the COVID-19 disease will be accepted. While we regret this action, it is required to focus BARDA's efforts on the immediate need. This policy will continue indefinitely. The latest BARDA BAA is amendment 13 describing these changes was posted on March 4, 2020.	White Papers Due: 10/31/20	Dependent upon proposal	<a href="https://www.mediccountermeasures.gov/barda/barda-baa/">https://www.mediccountermeasures.gov/barda/barda-baa/</a>  <a href="https://beta.sam.gov/opp/d1b6e601426e4e4c943235babdd4133a/view">https://beta.sam.gov/opp/d1b6e601426e4e4c943235babdd4133a/view</a>
6.	Strategic Technologies Office Broad Agency Announcement (DARPA) (DoD)	HR00112 OS0034	DARPA's Strategic Technology Office (STO) is seeking innovative ideas and disruptive technologies that provide the U.S. military increased lethality in an era of eroding dominance within the focus areas of the broader Mosaic Warfare objective: Mosaic Technologies, Mosaic Effects Web Services (EWS), and Mosaic Experimentation. Proposed research should investigate approaches that enable revolutionary advances in science, devices, or systems. The Defense Advanced Research Projects Agency (DARPA) anticipates funding a limited number of proposals under this BAA. Specifically excluded are existing mature solutions and research that primarily results in evolutionary improvements to existing technologies.	Proposal Due: 3/1/21	Dependent upon proposal	<a href="https://beta.sam.gov/opp/6b61760cf1914dd4baef3ce23fdc991c/view">https://beta.sam.gov/opp/6b61760cf1914dd4baef3ce23fdc991c/view</a>
7..	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD)	W81XW H18SBA A1	This BAA supports extramural research and development ideas for basic and applied research to support scientific study and experimentation directed toward advancing the state of the art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. Research and development funded through this BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease Research Program; Combat Casualty Care Research Program; Military Operational Research Program; Clinical and Rehabilitative Medicine Research Program; Medical Biological Defense Research Program; Medical Chemical Defense Research Program; Medical Simulation and Information Sciences Research Program.	No Due Dates, open till 9/30/22  Letter of Intent and Full Proposal Required	Dependent upon proposal, for up to 5 years	<a href="https://daks2k3a4ib2z.cloudfront.net/5552187c43c8fafa28fd470c/59d29ed69c3017000141dc1c_MT_EC%20Info.pdf">https://daks2k3a4ib2z.cloudfront.net/5552187c43c8fafa28fd470c/59d29ed69c3017000141dc1c_MT_EC%20Info.pdf</a>

8.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD)	W911NF-18-S-0005	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>Programs funded under this BAA include basic research, applied research, and advanced technology development that can improve human performance and Army readiness. Funding of R&amp;D within ARI areas of interest will be determined by funding constraints and priorities set during each budget cycle. Topic areas of basic research interest include: Understanding Team Dynamics; Improving Leadership and Leader Development; Identifying, Assessing, and Assigning Quality Personnel; Enhancing Lifelong Learning. ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.</p>	No Due Dates, open till 4/29/23  Full Proposal Required	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=304462">https://www.grants.gov/web/grants/view-opportunity.html?opId=304462</a>  (Full Announcement in Related Documents Tab)
9.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD)	W911NF-17-S-0002-07	The purpose of this Broad Agency Announcement (BAA) is to solicit research proposals in the engineering, physical, life, and information sciences for submission to the Army Research Office (ARO) for consideration for possible funding. ARL has an overarching technical strategy to support Strategic Land Power Dominance for the Army of 2030 and beyond. The strategy is based on seven Science and Technology (S&T) Core Technical Competencies: Computational Sciences, Ballistics Sciences, Materials & Manufacturing Sciences, Protection Sciences, Propulsion Sciences, Network & Information Sciences and Human Sciences.	No Due Dates, open till 3/31/22	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf</a>
10.	Army Research Office Broad Agency Announcement Staff Research Program (DoD)	W911NF 20S0003	The ARO is soliciting proposals for Staff Research Program opportunities. The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. The staff research will be performed collaboratively with institutions external to ARO. Staff research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences, when there is an intersection with the interests and capabilities of the participating external institutions in these basic research areas.	No Due Dates, open till 2/19/25	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf</a>



11.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD)	W911NF-17-S-0003	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The ARL BAA seeks proposals from institutions of higher education, nonprofit organizations, state and local governments, foreign organizations, foreign public entities, and for-profit organizations (i.e. large and small businesses) for research based on the following S&amp;T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Further details are described in the ARL Technical Strategy and in the ARL S&amp;T Campaigns located at <a href="http://www.arl.army.mil">www.arl.army.mil</a>. These documents are subject to periodic refinements which may result in taxonomy inconsistencies. These inconsistencies should not affect the efficacy of the BAA to present a complete portfolio of essential ARL research.</p>	No Due Dates, open till 3/31/22	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf">https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf</a>
12.	The USAID Global Health Broad Agency Announcement for Research and Development (2018) (USAID)	GLOBAL HEALTH -BAA-2018	This FOA seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.	Expression of Interest accepted on a rolling basis though 5/30/22; must be invited back for full proposal	Dependent upon proposal and award type	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=305999">https://www.grants.gov/web/grants/view-opportunity.html?opId=305999</a>  (Full Announcement in Related Documents Tab)
13.	Air Force Office of Scientific Research Broad Agency Announcement (DoD)	FA9550-18-S-0003	This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. For a full list of applicable research topics, see full solicitation.	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=305996">https://www.grants.gov/web/grants/view-opportunity.html?opId=305996</a>  (Full Announcement in Related Documents Tab)

14.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD)	W81XW H-18-S-SOC1	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care (PFC), human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. The equipment must be easy to use, require minimum maintenance, and have low power consumption. Drugs and biologics should not require refrigeration or other special handling. All materiel and related techniques must be simple and effective, and easily modified for commercialization. Research projects may apply existing scientific and technical knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements.</p>	<p>Submissions accepted through 7/31/23</p> <p>Submission of a pre-proposal is required</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=307754">https://www.grants.gov/web/grants/view-opportunity.html?opId=307754</a></p> <p>(Full Announcement in Related Documents Tab)</p>
15.	Army Applications Lab BAA for Disruptive Applications (DoD)	W911NF-19-S-0004	<p>AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi-domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch.</p>	<p>Submissions accepted through 5/1/24</p> <p>Submission of a pre-proposal is required</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=315517">https://www.grants.gov/web/grants/view-opportunity.html?opId=315517</a></p> <p>(Full Announcement in Related Documents Tab)</p>
16.	Disruptive Capabilities for Future Warfare (DARPA) (DoD)	HR001119S0054	<p>The Tactical Technology Office of the Defense Advanced Research Projects Agency is soliciting executive summaries, proposal abstracts and proposals for applied research, advanced technology development, and platform demonstrations that aim to enable disruptive capabilities for future warfare.</p>	<p>Proposal Due: 6/11/20</p>	<p>Up to \$1 million, for up to 1.5 years</p>	<p><a href="https://beta.sam.gov/opp/e7248da47889d975d0ccb0261d002a9a/view#general">https://beta.sam.gov/opp/e7248da47889d975d0ccb0261d002a9a/view#general</a></p>



17.	DSO Office-wide Broad Agency Announcement (DARPA) (DoD)	HR00111 9S0071	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The purpose of this BAA announcement is to identify and create next generation of scientific discovery by pursuing high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and transforming these initiatives into disruptive technologies for U.S. national security. In support of this mission, the DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts that address one or more of the following technical domains: (1) Frontiers in Math, Computation and Design, (2) Limits of Sensing and Sensors, (3) Complex Social Systems, and (4) Anticipating Surprise. Each of these domains is described below and includes a list of example research topics that highlight several (but not all) potential areas of interest. Proposals must investigate innovative approaches that enable revolutionary advances. DSO is explicitly not interested in approaches or technologies that primarily result in evolutionary improvements to the existing state of practice.</p>	Proposal Due: 6/12/20	Dependent upon proposal	<a href="https://beta.sam.gov/opp/22a346a8b55f0a7040d57a8fbc19e644/view">https://beta.sam.gov/opp/22a346a8b55f0a7040d57a8fbc19e644/view</a>
18.	Polyplexus Pilot 3 – DARPA Defense Sciences Office (DARPA) (DoD)	HR00111 9S0075	The Defense Sciences Office (DSO) at DARPA is seeking participants for a pilot program designed to utilize modern connectivity to rapidly develop promising basic research pathways leading to basic research proposals. DSO's intent is to fund research proposals resulting from this pilot program. As with other recent DARPA/DSO opportunity announcements, the goal of this program is to deliver research proposals that seek to investigate innovative approaches to enable revolutionary advances in science, devices, or systems. In particular, this announcement is intended to support the DSO mission to anticipate scientific surprise.	Proposal Due: 7/2/20	Dependent upon proposal	<a href="https://beta.sam.gov/opp/059d8cd9eda40b8ae04ed843732d0b6e/view#general">https://beta.sam.gov/opp/059d8cd9eda40b8ae04ed843732d0b6e/view#general</a>
19.	Long Range Broad Agency Announcement (BAA) for Basic and Applied Scientific Research (DoD/NRL)	N00173-19-S-BA01	The Naval Research Laboratory (NRL) The Naval Research Laboratory (NRL) is the Navy's corporate laboratory. NRL conducts basic and applied research for the Navy in a variety of scientific and technical disciplines. The basic research program is driven by perceptions about future requirements of the Navy. NRL is interested in receiving proposals for Long-Range Science and Technology (S&T) Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. For purposes of this BAA, S&T includes activities involving basic research, applied research, advanced technology development, and, under certain conditions, may include activities involving advanced component development and prototypes.	Estimated Proposal Due Date: 9/5/20	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=320355">https://www.grants.gov/web/grants/view-opportunity.html?opId=320355</a>  (Full Announcement in Related Documents Tab)

20.	Long Range Broad Agency Announcement (BAA) for Navy and Marine Corps Science & Technology (ONR, ONR Global, MCWL) (DoD)	N00014-20-S-B001	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The Office of Naval Research (ONR), ONR Global, and the Marine Corps Warfighting Lab (MCWL) are interested in receiving proposals for Long-Range Science and Technology (S&amp;T) Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR's broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines. Focus areas for the MCWL solicitation include, but not limited to: Expeditionary Logistics; Interoperable Command and Control (C2) Systems; C2 Afloat or the Naval Operational Architecture; Communications and Networking; Lightening the Load (Technologies that reduce the size and weight of the total load of the Marine Air Ground Task Force, as well as the individual Marine); Counter Improvised Explosive Device (IED) Mine; Persistent Intelligence, Surveillance and Reconnaissance (ISR); Urban Operations; Amphibious Operations Enablers; Precision Fired; Cyberspace Operations.</p>	Proposal Due: 9/30/20	Dependent upon proposal	<a href="https://www.onr.navy.mil/-/media/Files/Funding-Announcements/BAA/2020/N00014-20-S-B001.ashx">https://www.onr.navy.mil/-/media/Files/Funding-Announcements/BAA/2020/N00014-20-S-B001.ashx</a>
21.	United States Military Academy Broad Agency Announcement (DoD)	W911NF-20-S-0008	<p>The USMA BAA identifies topics of interest to the USMA departments, directorates, and research centers and institutes. These groups focus on executing in-house research programs, with a significant emphasis on collaborative research with other organizations. The groups fund a modest amount of extramural research in certain specific areas, and those areas are described in this BAA. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies.</p>	Proposals Accepted on Rolling Basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=325932">https://www.grants.gov/web/grants/view-opportunity.html?opId=325932</a>  (Full Announcement in Related Documents Tab)
22.	Broad Agency Announcement ADvanced Acclimation and Protection Tool for Environmental Readiness (ADAPTER) (DARPA) (DoD)	HR001120S0041	<p>While jet lag and traveler's diarrhea are inconveniences for an average traveler, they are critical challenges to operational readiness for a warfighter and can be the difference between mission success or failure. To maximize warfighter performance, the ADvanced Acclimation and Protection Tool for Environmental Readiness (ADAPTER) program will develop systems to provide warfighters control over their own physiology. This program will integrate engineered cells and biochemicals into an internal, bioelectronics carrier that the warfighter can signal, as needed, to initiate the production and release of therapies that either eliminate the principal cause of traveler's diarrhea - pathogenic bacteria - or regulate disrupted circadian rhythms caused by jetlag or shift work schedules.</p>	Abstract Due: 4/29/20  Proposal Due: 6/18/20	Dependent upon proposal, for up to 4.5 years	<a href="https://beta.sam.gov/opp/544fb519098641779a40f158f01851d2/view">https://beta.sam.gov/opp/544fb519098641779a40f158f01851d2/view</a>

23.	USSOCOM S&T Broad Area Announcement (DoD)	USSOCO M-BAAST-2020	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>United States Special Operations Command (USSOCOM), Special Operations Forces Acquisition, Technology, and Logistics (SOF AT&amp;L), Directorate of Science and Technology (S&amp;T), transformed the BAA infrastructure to better align with the USSOCOM Commander's strategic priorities and vision. As such, the S&amp;T Directorate will continue to evolve its investment strategy in FY21 and beyond by focusing on SOF modernization development efforts that include more encompassing, disruptive technology efforts that are larger in scope and meet the demands of the strategic vision and Future Operating Environment (FOE). USSOCOM will continue making some investments in Special Operations Forces (SOF) enhancements in the programs of record. S&amp;T seeks white papers in the areas of Next Generation Intelligence Surveillance and Reconnaissance, Networking and Data Management, Biotechnology and Human Interface, Next Generation Effects and Precision Strike, and Next Generation Mobility and Signature Management to build the Hyper Enabled Operator (see diagram below for a depiction of the HEO concept.</p>	Proposal Due: 5/21/20	Dependent upon proposal	<a href="https://beta.sam.gov/opp/bf402ce8c98a4998adbe789c878e1098/view?index=opp&amp;sort=relevance&amp;page=1&amp;keywords=BAAST&amp;opp_response_date_filter_model=%7B%22dateRange%22:%7B%22startDate%22:%22%22,%22endDate%22:%22%22%7D%7D&amp;date_filter_index=0&amp;inactive_filter_values=false&amp;utm_medium=email&amp;hsmi=87534449&amp;hsenc=p2ANqtz-8iJ-o4ggJGKOhQgOFNo ckdf6Qt_WXU_-Vn0jliGtDNdwnexCgZEiBnIFEXJBFXu_Hbui&amp;utm_content=87534449&amp;utm_source=hs_email">https://beta.sam.gov/opp/bf402ce8c98a4998adbe789c878e1098/view?index=opp&amp;sort=relevance&amp;page=1&amp;keywords=BAAST&amp;opp_response_date_filter_model=%7B%22dateRange%22:%7B%22startDate%22:%22%22,%22endDate%22:%22%22%7D%7D&amp;date_filter_index=0&amp;inactive_filter_values=false&amp;utm_medium=email&amp;hsmi=87534449&amp;hsenc=p2ANqtz-8iJ-o4ggJGKOhQgOFNo ckdf6Qt_WXU_-Vn0jliGtDNdwnexCgZEiBnIFEXJBFXu_Hbui&amp;utm_content=87534449&amp;utm_source=hs_email</a>
24.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	N/A	<p>The U.S. Department of Energy National Virtual Biotechnology Laboratory (NVBL) is a consortium of DOE National laboratories, each with core capabilities relevant to the threats posed by COVID-19. The NVBL is taking advantage of DOE user facilities, including light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying new targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks by harnessing extensive additive manufacturing capabilities. The NVBL collaborates extensively with researchers, both in academia and the private sector. In addition, the DOE user facilities are available to users in all sectors of the research community.</p>	N/A	Dependent upon solicitation and proposal	<a href="https://science.osti.gov/nvbl?utm_medium=email&amp;utm_source=FYI&amp;dm_i=1ZJN,6UU9U,RBBVZX,RI3TV,1">https://science.osti.gov/nvbl?utm_medium=email&amp;utm_source=FYI&amp;dm_i=1ZJN,6UU9U,RBBVZX,RI3TV,1</a>

			<b>CANCER (27)</b>			
25.	FY20 Prostate Cancer Research Program (PCRP) (DoD/CDMRP)	W81XW H-20-PCRP-EIRA; PRA; TSA; IDA; CTA; HDRA; PSORA; PCPRNA	<p>The FY20 Research Program has 7 award mechanisms:</p> <p><b>Early Investigator Research Award (EIRA)</b> supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated Mentors.</p> <p><b>Physician Research Award (PRA)</b> supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application.</p> <p><b>Translational Science Award (TSA)</b> supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY20 PCRP Overarching Challenges.</p> <p><b>Idea Development Award (IDA)</b> is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission.</p> <p><b>Clinical Trial Award (CTA)</b> is intended to accelerate the development of new interventions to decrease the burden of prostate cancer by supporting the rapid implementation of early-phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II).</p> <p><b>Health Disparity Research Award (HDRA)</b> supports promising research ideas that have high potential to make a significant impact in eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship.</p> <p><b>Population Science and Outcomes Research Award (PSORA)</b> supports population-focused studies that will, if successful, identify and understand predictors of lethal prostate cancer or improved survivorship within the context of the FY20 PCRP Overarching Challenges.</p>	<p>Pre-Application Due:</p> <p>6/4/20 6/25/20 8/27/20 9/10/20</p> <p>Proposal Due:</p> <p>6/18/20 7/16/20 9/24/20</p>	<p>Up to \$2 million per year, for up to 3 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://cdmrp.army.mil/funding/pa/FY20-PCRP-EIRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-PCRP-EIRA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-PCRP-PRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-PCRP-PRA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-PCRP-TSA.pdf">https://cdmrp.army.mil/funding/pa/FY20-PCRP-TSA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-PCRP-IDA.pdf">https://cdmrp.army.mil/funding/pa/FY20-PCRP-IDA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-PCRP-CTA.pdf">https://cdmrp.army.mil/funding/pa/FY20-PCRP-CTA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-PCRP-HDRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-PCRP-HDRA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-PCRP-PSORA.pdf">https://cdmrp.army.mil/funding/pa/FY20-PCRP-PSORA.pdf</a></p>

26.	New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional) (NIH)	PAR-20-170	<p style="text-align: center;"><b>CANCER</b></p> <p>The goal of this FOA is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA seeks applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration cancer registry data and to expand the data items collected. Applications must be built on partnership with U.S. population-based central cancer registries (a partnership must involve at least two different registries). Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research.</p>	<p>Letter of Intent Due: 10/18/20, 5/6/21</p> <p>Proposal Due: 11/18/20, 6/6/21</p>	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-170.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-170.html#_Section_II_Award_1</a>
27.	FY20 Melanoma Research Program (MRP) (DoD/CDMRP)	W81XW H-20-MRP-IA; MCAA; TSA; TDPA; TRA	<p>The MRP challenges the research community to redefine the concept of prevention. Melanomagenesis is a multi-step process initiating from normal melanocytes to dysplasia, through the development of melanoma and metastasis. A new paradigm of prevention may include detection, monitoring, and stopping the initiation of dysplasia, halting the progress to malignancy, blocking micro-metastases, or preventing emergence from tumor dormancy. The MRP acknowledges that each step along the disease process from initiation to metastasis is an opportunity to detect, monitor, and impede progression and to effect a cure. The MRP challenges the research community to prevent melanoma earlier in the disease cycle, thus preventing metastasis. The melanoma clinical, research, and patient community traditionally view prevention as the use of sunscreen/blockers to protect the melanocyte from harmful ultraviolet (UV) radiation. The MRP recognizes the usefulness of this strategy while tasking the research community <i>to redefine prevention to include the entire melanomagenesis process</i>. For more information on the MRP Challenge Statement, review <a href="https://cdmrp.army.mil/mrp/pdfs/Challenge%20statement.pdf">https://cdmrp.army.mil/mrp/pdfs/Challenge%20statement.pdf</a>. Six award mechanisms are provided.</p>	<p>Pre-Application Due: 6/22/20</p> <p>Proposal Due: 9/24/20</p>	<p>Up to \$700,000 for up to 3 years</p> <p>Dependent upon Award Mechanism</p>	<p><a href="https://cdmrp.army.mil/funding/pa/FY20-MRP-IA.pdf">https://cdmrp.army.mil/funding/pa/FY20-MRP-IA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-MRP-MCAA.pdf">https://cdmrp.army.mil/funding/pa/FY20-MRP-MCAA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-MRP-TSA.pdf">https://cdmrp.army.mil/funding/pa/FY20-MRP-TSA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-MRP-TDPA.pdf">https://cdmrp.army.mil/funding/pa/FY20-MRP-TDPA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-MRP-GAI.pdf">https://cdmrp.army.mil/funding/pa/FY20-MRP-GAI.pdf</a></p>

28.	FY20 Neurofibromatosis Research Program (NFRP) (DoD/CDMRP)	W81XW H-20- NFRP- CTA; EHDA; - NIA; EIRA; SIA; IIRA	<p style="text-align: center;"><b>CANCER</b></p> <p>The FY20 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Neurofibromatosis Research Program (NFRP) to support innovative, high-impact NF research through six award mechanisms. Areas of Emphasis: The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY20 Areas of Emphasis. Six different funding mechanisms are available. Not all Areas of Emphasis are applicable to every award mechanism. If the proposed research project does not address at least one of the FY20 NFRP Areas of Emphasis, justification should be provided it addresses an important problem related to NF research and/or patient care. Areas of emphasis include: (1) Biomarker discovery, utility, development, and validation (2) Non-tumor manifestations including pain, cognitive manifestation &amp; sleep (3) Heterogeneity of NF-related tumors, (4) Novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches, (4) Preclinical efficacy studies, (5) Target identification, drug discovery (6) Nutritional, environmental and other modifiers of NF, (7) Health services research</p>	<p>Pre-Application Due: 6/25/20</p> <p>Proposal Due: 7/9/20</p>	<p>Up to \$2 million, for up to 3 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://cdmrp.army.mil/funding/pa/FY20-NFRP-CTA.pdf">https://cdmrp.army.mil/funding/pa/FY20-NFRP-CTA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-NFRP-EHDA.pdf">https://cdmrp.army.mil/funding/pa/FY20-NFRP-EHDA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-NFRP-NIA.pdf">https://cdmrp.army.mil/funding/pa/FY20-NFRP-NIA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-NFRP-EIRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-NFRP-EIRA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-NFRP-SIA.pdf">https://cdmrp.army.mil/funding/pa/FY20-NFRP-SIA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-NFRP-IIRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-NFRP-IIRA.pdf</a></p>
-----	--	---	--	---	---	---



29.	FY20 Breast Cancer Research Program (BCRP) (DoD/CDMRP)	W81XW H-20-BCRP-BTA12-2; BTA3-2; - BTA4-2; EOHS-2; INNOV2; TBCCA	<p style="text-align: center;"><b>CANCER</b></p> <p>The BCRP has prepared a brief overview, The Breast Cancer Landscape, that describes what is currently known about the most pertinent topics that are consistent with the BCRP’s mission of ending breast cancer. Applicants are strongly urged to read and consider The Breast Cancer Landscape before preparing their applications. The Breast Cancer Landscape may be found at <a href="https://cdmrp.army.mil/bcrp/pdfs/Breast%20Cancer%20Landscape.pdf">https://cdmrp.army.mil/bcrp/pdfs/Breast%20Cancer%20Landscape.pdf</a> ) The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations.</p>	<p>Pre-Application Due: 6/24/20, 9/6/20</p> <p>Proposal Due: 10/6/20, 9/22/20</p>	<p>Up to \$20 million for up to 4 years</p> <p>Dependent Upon Award Mechanism</p>	<p><a href="https://cdmrp.army.mil/funding/pa/FY20-BCRP-BTA12-2.pdf">https://cdmrp.army.mil/funding/pa/FY20-BCRP-BTA12-2.pdf</a> ;</p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-BCRP-BTA3-2.pdf">https://cdmrp.army.mil/funding/pa/FY20-BCRP-BTA3-2.pdf</a> ;</p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-BCRP-BTA4-2.pdf">https://cdmrp.army.mil/funding/pa/FY20-BCRP-BTA4-2.pdf</a> ;</p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-BCRP-EOHS-2.pdf">https://cdmrp.army.mil/funding/pa/FY20-BCRP-EOHS-2.pdf</a> ;</p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-BCRP-INNOV-2.pdf">https://cdmrp.army.mil/funding/pa/FY20-BCRP-INNOV-2.pdf</a> ;</p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-BCRP-TBCCA.pdf">https://cdmrp.army.mil/funding/pa/FY20-BCRP-TBCCA.pdf</a></p>
-----	--	--	---	---	---	---

CENTRAL NERVOUS SYSTEM (1)						
30.	Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01/R21 Clinical Trials Not Allowed) (NIH)	PAR-20-165 (R01) PAR-20-166 (R21)	<p>This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. The R21 Grant mechanism is intended to support innovative, high impact research projects. Such projects would either 1) generate pilot data to assess the feasibility of a novel avenue of investigation; 2) involve high risk experiments that could lead to a breakthrough in ME/CFS; 3) demonstrate the feasibility of new technologies that could have a major impact on ME/CFS research. Proposals submitted under this mechanism should be limited to those with the potential for truly ground-breaking impact.</p>	Proposal Due: 6/5/20, 6/16/20	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-165.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-165.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-168.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-168.html#_Section_II._Award_1</a>

CLINICAL RESEARCH (2)						
31.	Research Project Grant (Parent R01) Clinical Trial, Basic Experimental Studies with Humans Required, Clinical Trial Not Allowed) (NIH)	PA-20-183; 184; 185	The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.	Proposal Due: 6/5/20, 10/5/20, 2/5/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-20-185.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-20-185.html#_Section_II._Award_1</a>
32.	Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required, Clinical Trial Not Allowed, Basic Experimental Studies with Humans Required)	PA-20-194; 195; 196	The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.	Proposal Due: 6/16/20, 10/16/20, 2/16/21	Up to \$275,000, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-196.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-196.html#_Section_II._Award_1</a>

<b>CHRONIC LUNG DISEASE (1)</b>						
33.	Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) Disease Modifying Therapies for Chronic Lung Diseases (U24 Clinical Trial Required – Infrastructure & Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required) (NIH)	RFA-HL-21-012  RFA-HL-21-013	The purpose of this limited FOA is to support the continuation and expansion of the existing NHLBI Pulmonary Trials Cooperative (PTC) clinical trials network. FOA 21-012 requests applications for a cooperative agreement research grant (U24) to serve as the Network Management Core (NEMO) for the PTC. The PTC will include multiple Protocol Leadership Groups (PLGs) and a single Network Management Core (NEMO) and will conduct multiple simultaneous phase II clinical trials that will test innovative disease modifying therapies (DMT) for adult chronic lung diseases. NEMO will have primary responsibility for organizing and operating this multi-center cooperative. A companion FOA (RFA-HL-21-013) seeks Protocol Leadership Group (PLG) applications for specific phase II DMT trials. FOA 21-013 seeks Protocol Leadership Group (PLG) applications for specific phase II DMT trials.	Letter of Intent Due: 6/24/20  Proposal Due: 7/24/20	Up to \$17 million, for up to 7 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-012.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-012.html#_Section_II_Award_1</a>
<b>CORONAVIRUS (28)</b>						
34.	Pre-Announcement ATSDR's Partnership to Promote Local Efforts To Reduce Environmental Exposure - COVID-19 Supplement (CDC)	CDC-RFA-TS20-20010101 SUPP20	The purpose of this funding announcement is to support state health departments in their response to the COVID-19 pandemic. Potential COVID-19 related work under this supplemental funding opportunity may include providing guidance and engagement on safe practices for disinfection for home, school and early learning education centers, and assist in COVID-19 response and prevention efforts by conducting environmental assessments, establishing plans for addressing environmental impacts, and strengthening partnerships among the environmental, epidemiological, and laboratory responses.	Estimated Post Date: 5/1/20  Estimated Proposal Due Date: 5/8/20	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326478">https://www.grants.gov/web/grants/view-opportunity.html?opId=326478</a>

35.	Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) (NIH)	PA-20-070	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards, (except R13s, T32s, F32s), that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. This FOA does not include grants that were previously funded under FOAs supported by Patient Centered Outcome Research Trust Fund (PCOR TF) dollars (Please see FOA number PA-20-072, which is directed towards those grants). Applications must be responsive to AHRQ’s mission, which is to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with the U.S. Department of Health and Human Services (HHS) and with other partners to make sure that the evidence is understood and used. Within the mission, AHRQ’s specific priority areas of focus are detailed here: <a href="https://www.ahrq.gov/funding/policies/foaguidance/index.html">https://www.ahrq.gov/funding/policies/foaguidance/index.html</a>.</p>	Proposal Due: 5/29/20	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-070.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-070.html#_Section_II._Award_1</a>
36.	Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) (NIH)	PA-20-072	<p>The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards that were funded under the PCOR FOAs, (see above: Part 1. Overview Information, Activity Code list), that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. This FOA does not include grants that were awarded using AHRQ Health Service Research (HSR) dollars (please see FOA number PA-20-070, which is directed toward those grants). It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the ongoing research to develop high-impact new knowledge concerning COVID-19.</p>	Proposal Due: 5/29/20	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-072.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-072.html#_Section_II._Award_1</a>

37.	Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01/R21 Clinical Trial Not Allowed) (NIH)	PAR-20-178; 177	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). Areas of high priority include, but are not limited to, the following:</p> <ul style="list-style-type: none"> <li>• Development or improvement of clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity and specificity</li> <li>• Development of SARS-CoV-2-specific or broadly protective coronavirus vaccine candidates including: novel antigen design strategies, novel platforms or delivery approaches, addition of adjuvants</li> </ul>	Applications will be accepted on a rolling basis, beginning on 4/30/2020	Dependent upon Proposal for up to 5 years  Dependent upon funding mechanism	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-178.html#_Section_II._Award_1;">https://grants.nih.gov/grants/guide/pa-files/PAR-20-178.html#_Section_II._Award_1;</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-177.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-177.html#_Section_II._Award_1</a>
38.	Fast-Track Program for COVID-19 Test Development and Distribution Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing (NIH)	N/A	The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to \$500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public's safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.	Proposals Accepted on a rolling basis	Dependent upon proposal	<a href="https://www.poctrn.org/radx">https://www.poctrn.org/radx</a>



39.	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences (NIH)	NOT-OD-20-097 PA-18-395 PA-18-591	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>This NOSI highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts, including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health. Applications in response to this NOSI must be submitted using the following targeted funding opportunities or subsequent re-issued equivalents: PA-18-935, PA-18-591.</p>	Proposals accepted on a rolling basis	Up to \$100,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-097.html">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-097.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-591.html#_Section II. Award 1</a>
40.	Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-HL-20-004 PA-18-591 PA-18-935	<p>NIDCD is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NIDCD's scientific mission areas of hearing, balance, taste, smell, voice, speech and language. In order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, NIDCD is encouraging the submission of applications for supplements to active NIDCD grants to address the pathology, prevention, diagnosis, sequelae, or treatment of COVID-19 directly related to NIDCD's mission areas. Applications are expected to focus on immediate needs to help address the COVID-19 pandemic in a timely manner. Applications that are not responsive will be withdrawn without review. Applications for this initiative must be submitted using the solicitations PA-18-591 and PA-18-935.</p>	Proposals accepted on a rolling basis until 6/1/20	Up to \$125,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DC-20-004.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DC-20-004.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II. Award 1</a>

41.	COVID-19 Targeted PFA (PCORI)	N/A	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The objectives of this funding announcement are to (1) strengthen the understanding of different approaches to improve the impact of COVID-19 on individuals, communities, healthcare providers, and healthcare systems; and (2) provide evidence to inform clinical and public health responses, decision making, and planning. This announcement has three targeted priority areas: (1) Adaptations to health care delivery, (2) Impact of COVID-19 on vulnerable populations, and (3) Impact of COVID-19 on healthcare workforce well-being, management, and training.</p>	Proposal Due: 5/26/20	Up to \$5 million, for up to 2 years	<a href="https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-COVID19-Targeted-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-COVID19-Targeted-PFA.pdf</a>
42.	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK (NIH)	NOT-DK-20-018 PA-18-935	NIDDK is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDDK is particularly interested in projects focusing on the direct action of the virus on kidney, gastrointestinal tract function, and the endocrine/metabolic system, and the collection of biosamples that will inform the understanding of renal, gastrointestinal, and endocrine/metabolic sequelae of viral infection. Pilot clinical studies (observational and interventional) that support the understanding or treatment of COVID-19-related diseases within the mission of the NIDDK are also of interest. NIDDK will only consider applications that propose projects that may lead to rapid translation and impact in the COVID-19 emergency to be responsive to this NOSI. Applications for this initiative must be submitted using the PA-18-935.	Proposals accepted on a rolling basis until 6/1/20	Up to \$500,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-018.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-018.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II_Award_1</a>
43.	Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-DK-20-ES-20-015 PA-18-935 RFA-ES-19-011	NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. Applications for this initiative must be submitted using opportunity PA-18-935.	Proposals accepted on a rolling basis until 5/3/21	Dependent on proposal, for up to 2 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-015.html">https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-015.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-011.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-011.html#_Section_II_Award_1</a>

44.	Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-CA-20-043 PA-18-935	The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19). To accelerate the development of promising technologies, the NCI encourages applications from small businesses with NCI-funded active SBIR/STTR awards for technologies that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19). Applications for this initiative must be submitted using opportunity PA-18-935.	Proposal Due: 6/25/20	Up to \$250,000 for Phase I and up to \$1 million Phase II (SBIR) and \$500,000 (STTR)	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-043.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-043.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II. Award 1</a>
45.	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus (NIH)	NOT-TR-20-016 PA-18-591	NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines. A multi-organ on chip approach is strongly encouraged though not required. Please document access to a BSL-3 facility or include scientific justification for use of alternative facilities, for example using an engineered a COVID-19 pseudovirus that expresses the key surface Spike protein, which mediates its entry into cells. Applications for this initiative must be submitted using opportunity PA-18-591.	Proposals accepted on a rolling basis until 1/25/22	Dependent on proposal, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II. Award 1</a>

46.	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NIH)	NOT-MH-20-047 PA-18-591 PA-18-935	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Applications for this initiative must be submitted using opportunities PA-18-591 or PA-18-935.</p>	Proposals accepted on a rolling basis until 4/15/21	Dependent on proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II. Award 1</a>
47.	Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus (NIH)	NOT-TR-20-017 PA-18-135	<p>NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines. This Notice announces the availability of competitive revisions for investigators and institutions funded through The NIH Microphysiological Systems (MPS) Program; or SBIR/STTR-supported investigators, provided the award involves tissue chips; or Microphysiological systems programs from across NIH. PA-20-135 or its reissued equivalent must be used for submissions for this initiative.</p>	Proposals accepted on a rolling basis until 1/25/22	Dependent on proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-017.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-017.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section II. Award 1</a>

48.	Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NIH)	NOT-TR-20-019  PA-18-591  PA-18-935	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>This NOSI is soliciting research in health disparity populations that - seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations. Outcomes of interest include, but are not limited to, the COVID-19 incidence, prevalence, and mortality rates in defined populations; substance abuse and mental health effects; impact on chronic conditions; effects on severe maternal morbidity and mortality; and influence on access, utilization, and quality of health care (including needed medical care, medical treatments, and access to prescription drugs). Applications for this initiative must be submitted using opportunities PA-18-591 or PA-18-935.</p>	Proposals accepted on a rolling basis until 5/1/21	Up to \$125,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II._Award_1</a>
49.	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission (NIH)	NOT-TR-20-020  PA-18-935	<p>NIDDK is issuing this Notice of Special Interest (NOSI) in response to the urgent need for research on how coinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent for Coronavirus Disease 2019 (COVID-19), might affect HIV-associated comorbidities, coinfections, and complications (CCCs) within its mission. NIDDK supports biomedical research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases. For this funding opportunity announcement, NIDDK is interested in studies to elucidate if COVID-19 might provoke or exacerbate noncommunicable gastrointestinal, liver, kidney/urological and metabolic/endocrine diseases in people with HIV (PWH) or worsen the consequences of viral hepatitis coinfection. Conversely, it is also important to elucidate whether people with HIV (PWH) with CCCs within the mission of NIDDK have different COVID-19 outcomes. Studies are expected to align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR) in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Applications for this initiative must be submitted using PA-18-935.</p>	Proposals accepted on a rolling basis until 6/1/20	Up to \$500,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-020.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-020.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II._Award_1</a>

50.	Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-TR-20-042 PA-18-935 PA-18-591	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa. Topics of specific interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infected persons in the context of cancer. Applications for this initiative must be submitted using opportunities PA-18-591 or PA-18-935.</p>	Proposals accepted on a rolling basis until 6/25/20	Up to \$100,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-042.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-042.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1</a>
51.	Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-AT-20-011 PA-18-935 PA-18-591	NCCIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections. . Applications for this initiative must be submitted using opportunities PA-18-591 or PA-18-935.	Proposals accepted on a rolling basis until 10/6/20	Dependent upon proposal, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-at-20-011.html">https://grants.nih.gov/grants/guide/notice-files/not-at-20-011.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1</a>



52.	Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-EB-20-006 PA-19-270 PA-19-272 PA-19-631	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>NIBIB is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19). The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Example technologies include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Rapid point-of-care and home-based testing/diagnostics</li> <li>• Wearable, implantable, and remote sensors/imagers for physiological monitoring</li> <li>• Medical imaging technologies and algorithms/artificial intelligence (AI) for rapid detection, diagnosis, and monitoring of lung infection</li> </ul> <p>Applications for this initiative must be submitted using opportunities PA-19-270, PA-19-272, PA-19-631</p>	Proposals accepted on a rolling basis until 3/31/21	Dependent upon proposal	<p><a href="https://grants.nih.gov/grants/guide/notice-files/not-eb-20-006.html">https://grants.nih.gov/grants/guide/notice-files/not-eb-20-006.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/pa-19-270.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/pa-19-270.html#_SectionII_Award1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/pa-19-272.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/pa-19-272.html#_SectionII_Award1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-631.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-631.html#_SectionII_Award1</a></p>
-----	---	--	--	---	-------------------------	---

53.	Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-EB-20-007 PAR-19-056 PAR-18-418 PAR-18-530 PAR-18-155 PAR-18-084 PAR-18-433 PAR-18-052	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>NIBIB is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19). The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Example technologies include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Rapid point-of-care and home-based testing/diagnostics</li> <li>• Wearable, implantable, and remote sensors/imagers for physiological monitoring</li> <li>• Medical imaging technologies and algorithms/artificial intelligence (AI) for rapid detection, diagnosis, and monitoring of lung infection</li> </ul> <p>Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents: PA-19-056, PA-18-418, PA-18-530, PA-20-155, PA-20-084, PA-20-433, PA-19-052</p>	Proposals accepted on a rolling basis until 3/31/21	Dependent upon proposal, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/not-eb-20-007.html">https://grants.nih.gov/grants/guide/notice-files/not-eb-20-007.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-056.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-19-056.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-418.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-418.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-530.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-530.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-155.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-155.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-084.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-084.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-433.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-433.html#_Section_II_Award_1</a>
-----	---	---	---	---	--	---

54.	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-EB-20-008 PA-20-135 PA-18-591	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>NIBIB is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19). The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Example technologies include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Rapid point-of-care and home-based testing/diagnostics</li> <li>• Wearable, implantable, and remote sensors/imagers for physiological monitoring</li> <li>• Medical imaging technologies and algorithms/artificial intelligence (AI) for rapid detection, diagnosis, and monitoring of lung infection</li> </ul> <p>Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents: PA-20-135, PA-18-591</p>	Proposals accepted on a rolling basis until 11/20/20	Dependent upon proposal, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/not-eb-20-008.html">https://grants.nih.gov/grants/guide/notice-files/not-eb-20-008.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section II_Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II_Award 1</a>
55.	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-LM-20-010 PA-18-591	<p>NLM is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NLM's strategic goal of fostering data driven research. In order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, NLM is encouraging the submission of applications for administrative supplements to active NLM R01 grants to address the following research areas of interest:</p> <ul style="list-style-type: none"> <li>• Methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, or other relevant topics such as discovery of risks for infection by SARS-Cov-2 viruses, use of standard terminologies for these viruses in federated health data sets</li> <li>• Public health surveillance methods that mine genomic, viromic, health data, environmental data and/or data from other pertinent sources such as social media, to identify spread and impact of SARS-Cov-2.</li> </ul> <p>Applications in response to this NOSI must be submitted using the opportunity PA-18-591.</p>	Proposal Due: 6/1/20	Up to \$75,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-lm-20-010.html">https://grants.nih.gov/grants/guide/notice-files/not-lm-20-010.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II_Award 1</a>

56.	<p>Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA (NIH)</p>	<p>NOT-AA-20-011  PA-18-591  PA-18-935</p>	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>NIAAA is encouraging research in the following areas, including those that capitalize on existing research cohorts, to investigate urgent research questions of significance to the COVID-19 pandemic within the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless. Questions that may be addressed under this NOSI include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Are individuals who engage in high-risk drinking behaviors or with AUD more likely to engage in behaviors that increase risks for infection or transmission of SARS-CoV-2?</li> <li>• What is the influence of alcohol drinking history, patterns, amount, and duration on susceptibility to SARS-CoV-2 infection and COVID-19 prevalence, progression, and outcomes?</li> <li>• What are the common mechanisms of alcohol-associated Acute Respiratory Distress Syndrome (ARDS) and COVID-19-related ARDS? Applications in response to this NOSI must be submitted using the opportunities PA-18-591 and PA-18-935.</li> </ul>	<p>Proposals accepted on a rolling basis until 4/15/21</p>	<p>Up to \$100,000 per year, for up to 2 year</p>	<p><a href="https://grants.nih.gov/grants/guide/notice-files/not-aa-20-011.html">https://grants.nih.gov/grants/guide/notice-files/not-aa-20-011.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II_Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section II_Award_1</a></p>
57.	<p>Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs (NIH)</p>	<p>NOT-TR-20-028  PA-20-135  PA-18-591</p>	<p>The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients. Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice and designate “NOT-TR-20-028” (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&amp;R) Form as directed below.</p>	<p>Proposals accepted on a rolling basis until 11/10/20</p>	<p>Up to \$100,000 per year, for up to 2 year</p>	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-028.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-028.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section II_Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II_Award_1</a></p>

58.	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-RM-20-015  PA-20-135	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The Office of Strategic Coordination (OSC), which manages the Common Fund, is issuing this Notice of Special Interest (NOSI) to stimulate innovative research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the disease it causes, Coronavirus Disease 2019 (COVID-19). OSC seeks new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. The funding for this supplement is provided from the Coronavirus Aid, Relief, and Economic Security (CARES) Act, 2020. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.</p>	Proposals accepted on a rolling basis until 6/19/20	Dependent upon proposal, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-015.html">https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-015.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII_Award1</a>
59.	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System (NIH)	NOT-NS-20-051  PA-18-935  PA-18-591	NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS's scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. Applications in response to this NOSI must be submitted using the opportunities PA-18-935 and PA-18-591.	Proposals accepted on a rolling basis until 4/14/21	Up to \$200,000, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-ns-20-051.html">https://grants.nih.gov/grants/guide/notice-files/not-ns-20-051.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII_Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII_Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII_Award1</a>

60.	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR (NIH)	NOT-DE-20-022 PA-18-591 PA-18-935	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>NIDCR encourages submission of applications on the following topic areas of potentially <b>immediate and high impact</b> in combatting COVID-19.</p> <ul style="list-style-type: none"> <li>• Modifications to dental practice and/or treatment space to prevent aerosol and droplet pathogen transmission</li> <li>• Determination of the extent to which viral pathogens are transmitted via aerosol and droplet routes during treatment in dental settings</li> <li>• Design and implementation of strategies to achieve the <a href="https://www.cdc.gov/od/oc/media/press/2020/s200202.html">Center for Disease Control and Prevention (CDC) second-tier Transmission-Based Precautions</a> in dental practice</li> <li>• Implementation of disinfection processes to ensure treatment spaces and equipment are devoid of transmissible viral pathogens</li> <li>• Development of interventions to protect health care workers, other front-line professionals, and patients from viral transmission</li> </ul> <p>Applications in response to this NOT must be submitted using the opportunities PA-18-935 and PA-18-591.</p>	Proposal due: 6/1/20, 11/2/20	Up to \$150,000, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-de-20-022.html">https://grants.nih.gov/grants/guide/notice-files/not-de-20-022.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html#_SectionII_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html#_SectionII_Award_1</a>
61.	Notice of Special Interest (NOSI): Infrastructure Access for Research on Coronavirus Disease 2019 (COVID-19) Conducted in the National Dental Practice-Based Research Network (NIH)	NOT-DE-20-023 PAR-20-073	<p>National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) conducted in the National Dental Practice-Based Research Network (PBRN). NIDCR will place a high priority on topics that would be of <b>immediate and high impact</b> to protect and ensure the safety of personnel and patients in dental practices, prevent SARS-CoV-2 transmission, and improve detection and diagnosis of COVID-19. Successful X01 applicants will be given access to the National Dental PBRN infrastructure to support an individual project. Successful applications will utilize the resources of and be funded through the National Dental PBRN Administrative and Resource Center and/or National Coordinating Center for study planning and implementation. Applications in response to this NOSI must be submitted using the opportunity PAR-20-073.</p>	Proposal due: 6/1/20, 11/2/20	Dependent upon proposal, to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-de-20-023.html">https://grants.nih.gov/grants/guide/notice-files/not-de-20-023.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-073.html#_SectionII_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-073.html#_SectionII_Award_1</a>



<b>DIABETES (2)</b>						
62.	Observational Analyses of Second-Line Pharmacological Agents in Type 2 Diabetes (PCORI)	N/A	Through this initiative, PCORI seeks to fund high-quality studies using observational designs that compare the effectiveness of newer versus older second-line pharmacological agents in type 2 diabetes mellitus (T2DM) among individuals at moderate cardiovascular risk (2-3 percent risk of events per year). PCORI is interested in studies that compare newer medication classes (SGLT2 inhibitors and GLP-1 receptor agonists) to older, lower-cost treatments (sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors). These studies should address whether the newer agents offer true benefits in terms of cardiovascular disease endpoints and how large any benefits may be. PCORI is particularly interested in medication comparisons for patients whose baseline cardiovascular risk is lower than among those who participated in the published clinical trials.	Letter of Intent Due: 6/2/20  Proposal Due: 9/1/20	Up to \$4 million, for up to 3 years	<a href="https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-Observational-T2DM-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-Observational-T2DM-PFA.pdf</a>
63.	PCORI Funding Announcement: Conducting Rare Disease Research Using PCORnet® (PCORI)	N/A	PCORI intends to pursue this limited competition opportunity, open to all PCORnet® Clinical Research Networks (CRNs)/Health Plan Research Networks (HPRNs) and their partner organizations to perform an observational research study that will answer one or more important research questions about the care of patients with rare diseases. A secondary goal is to enhance the capabilities for the conduct of multi-site rare disease research by creating partnerships, methods, tools, and linkages that will facilitate future comparative effectiveness studies for the rare disease community. Through this initiative, PCORI seeks to fund high-quality observational cohort studies of people with rare diseases or conditions.	Letter of Intent Due: 6/2/20  Proposal Due: 9/1/20	Up to \$3.5 million, for up to 3 years	<a href="https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-Rare-Disease-PCORnet-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-Rare-Disease-PCORnet-PFA.pdf</a>
<b>EATING DISORDERS (1)</b>						
64.	Post-Acute Interventions for the Treatment of Anorexia Nervosa (R34 Clinical Trial Required) (NIH)	RFA-MH-20-500	NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of interventions targeting sustained and enhanced treatment response following acute treatment for anorexia nervosa (AN). An emphasis is placed on trials that go beyond seeking incremental gains in intervention effects, and instead take a theory-driven, empirical approach to developing and testing interventions that will have a significant impact on weight restoration and psychological symptoms associated with AN. Consistent with an effectiveness framework, studies should take a deployment-focused approach to intervention development and testing, acknowledging that many patients will receive post-acute treatment from community providers unaffiliated with specialty eating disorder centers.	Letter of Intent Due: 9/19/20, 5/15/21  Proposal Due: 10/19/20, 6/15/21	Up to \$445,000, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-500.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-500.html#_Section_II_Award_1</a>

FETAL ALCOHOL SPECTRUM DISORDERS (1)						
65.	Supporting Fetal Alcohol Spectrum Disorders Screening and Intervention (HRSA)	HRSA-20-111	<p>This notice announces the opportunity to apply for funding under the Supporting Fetal Alcohol Spectrum Disorders Screening and Intervention program. This program has two related purposes: to reduce alcohol use among pregnant women, and to improve developmental outcomes for children and adolescents with a suspected or diagnosed Fetal Alcohol Spectrum Disorder (FASD), in states, U.S. territories, tribes/tribal organizations, or communities that have high rates of binge drinking among pregnant women, especially in rural areas. Specifically, the goals of this program are: 1) to improve the ability of primary care providers (PCPs) serving pregnant women, to screen their patient population for alcohol use, provide brief intervention, and refer high-risk pregnant women to specialty care; and, 2) to improve the ability of PCPs serving children and adolescents to screen their patient population for prenatal alcohol exposure among those suspected of FASD, and manage and provide referrals to necessary services for those identified with FASD.2 PCPs may include, but are not limited to, maternity care, family medicine, pediatric and nursing providers, especially those practicing in rural areas3 and medically underserved communities.4 The recipient will use a variety of evidence-based modalities including telehealth approaches, to increase PCP knowledge and provide technical assistance (TA) to implement and sustain practice change among PCPs.</p>	Proposal Due: 6/9/20	Up to \$1,000,000, for up to 3 years	<a href="https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=a370d5b2-e191-4deb-ace3-314704c22f20">https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=a370d5b2-e191-4deb-ace3-314704c22f20</a>

<b>HEARING LOSS (1)</b>						
66.	FY20 Hearing Restoration Research Program (HRRP) (DoD/CDMRP)	W81XW H-20-HRRP-FRA	<p>To meet the intent of the award mechanism, all applications to the FY20 HRRP FRA must address research in one or more of the following Focus Areas:</p> <ul style="list-style-type: none"> <li>Accelerate translation of biological regeneration/repair mechanisms into therapies that treat auditory system injury and restore auditory function. For example, but not limited to: <ul style="list-style-type: none"> <li>Hair cell regeneration/repair/recovery</li> <li>Neural regeneration/repair/recovery</li> <li>Treatment for synaptopathy and hidden hearing loss</li> </ul> </li> <li>Diagnostic tests that help differentiate sensory, neural, synaptic, and central processing disorders, that may inform applicability and outcomes for current or future hearing restoration therapeutics.</li> <li>Develop reliable in-vitro human models to facilitate the understanding, derivation, and characterization of human auditory cells, and/or to facilitate the evaluation of hearing restoration therapies.</li> <li>Develop and/or validate techniques/methods beyond the audiogram to diagnose acute auditory system injury in austere or remote environments. For example, but not limited to, simple and rapid assessments that are compatible with portable platforms.</li> </ul>	<p>Pre-Application Due: 7/14/20</p> <p>Proposal Due: 11/3/20</p>	<p>Up to \$1.25 million, for 3 years</p> <p>Dependent upon funding level</p>	<p><a href="https://cdmrp.army.mil/funding/pa/FY20-HRRP-FRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-HRRP-FRA.pdf</a></p>
<b>HYPERCHOLESTEROLEMIA (1)</b>						
67.	Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia (FH) (R61/R33 Clinical Trial Required) (NIH)	RFA-HL-22-006	<p>This milestone-driven FOA invites applications for single-site clinical trials that: (1) address barriers that impede population-level implementation of case finding and cascade screening (i.e., blood relatives of FH index cases are systematically contacted based on their risk according to the pattern of inheritance); (2) explore implementation science methodologies to assess the uptake, cost-effectiveness, feasibility, and scalability of family-based cascade screening programs for familial hypercholesterolemia (FH); (3) develop or improve machine learning algorithms and data mining techniques to find high-risk individuals using electronic health records (EHRs); and (4) optimize treatment strategies and health outcomes.</p>	<p>Letter of Intent Due: 2/8/21</p> <p>Proposal Due: 3/8/21</p>	<p>Up to \$450,000 per year, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-006.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-006.html#_Section_II_Award_1</a></p>

<b>IMAGING (1)</b>						
68.	National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional) (NIH)	PAR-20-169	This Funding Opportunity Announcement (FOA) encourages grant applications for National Centers for Biomedical Imaging and Bioengineering (NCBIB). NCBIB are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. NCBIB also make their technologies available to other investigators, train members of the research community in the use of the technologies and disseminate the technologies broadly.	Letter of Intent Due: 6/25/20, 10/25/20  Proposal Due: 9/25/20, 1/25/21	Up to \$1.25 million, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-169.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-169.html#_Section_II_Award_1</a>
<b>IMMUNOLOGY &amp; IMMUNE SYSTEMS (1)</b>						
69.	Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed) (NIH)	RFA-AI-20-027	The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from institutions/organizations to participate in a cooperative research group, the Mucosal Immunology Studies Team (MIST), focusing on immune mechanisms and immune regulation at mucosal surfaces of the respiratory, gastrointestinal and urogenital tracts. The main objective of this program is to break new ground in the understanding of basic mucosal immune mechanisms by introducing new ideas, approaches and technologies that address the difficult questions in mucosal immunology.	Letter of Intent Due: 9/9/20  Proposal Due: 10/9/20	Up to \$350,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-027.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-027.html#_Section_II_Award_1</a>
<b>MATERNAL HEALTH (1)</b>						
70.	Notice of Special Interest: Administrative Supplements for NIH grants to Add or Expand Research Focused on Maternal Mortality (NIH)	NOT-OD-20-104  PAR-019-591	In order to rapidly improve our understanding of the leading causes of pregnancy-related and pregnancy-associated morbidity, including severe maternal morbidity (SMM), and maternal mortality (MM) during pregnancy, at delivery, and up to one year post-partum and to expand research and development of risk stratification approaches and mitigation strategies, NIH is soliciting the submission of applications for Administrative Supplements to active social, biobehavioral, and fundamental science awards. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches. Applications for this initiative must be submitted using solicitation PA-18-591.	Proposal Due: 6/22/20	Up to \$150,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-104.html">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-104.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1</a>

			<b>MULTIMORBIDITY (2)</b>			
71.	Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional) (NIH)	PAR-20-179	This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs.	Proposal Due: 10/5/20, 2/5/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-179.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-179.html#_Section II. Award 1</a>
72.	Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional) (NIH)	PAR-20-180	This Funding Opportunity Announcement (FOA) invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs) and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. The National Cancer Institute is interested in observational and intervention research to understand and promote primary, secondary, and tertiary prevention of multimorbidity for cancer survivors ( <a href="https://cancercontrol.cancer.gov/ocs/statistics/index.html#definition-survivorship">https://cancercontrol.cancer.gov/ocs/statistics/index.html#definition-survivorship</a> ), and the prevention of cancer among those diagnosed with other chronic conditions (e.g., diabetes, hypertension, obesity).	Proposal Due: 10/5/20, 2/5/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-180.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-180.html#_Section II. Award 1</a>

<b>MULTIPLE SCLEROSIS (1)</b>						
73.	FY20 Multiple Sclerosis Research Program (MSRP) (DoD/CDMRP)	W81XW H-19-MSRP-EHDA; CTA; IIRA	All applications submitted to the FY20 MSRP Exploration – Hypothesis Development Award (EHDA) and the Investigator-Initiated Research Award (IIRA) Programs <i>must</i> address at least one of the following Focus Areas: Central Nervous System Regenerative Potential in Demyelinating Conditions, Correlates of Disease Activity and Progression in Multiple Sclerosis, Biology and Measurement of Multiple Sclerosis Symptoms, Factors Contributing to Multiple Sclerosis Etiology, Prodrome, Onset, and Evolution. All applications submitted to the FY20 MSRP Clinical Trial Award (CTA) Program must address at least one of the following Focus Areas: Promoting Repair, Neuroprotection, and Remyelination in Multiple Sclerosis, Treatment of Multiple Sclerosis Symptoms.	Pre-Application Due: 6/17/20  Proposal Due: 10/1/20	Up to \$1.5 million, for up to 4 years  Dependent upon Award Mechanism	<a href="https://cdmrp.army.mil/funding/pa/FY20-MSRP-EHDA.pdf">https://cdmrp.army.mil/funding/pa/FY20-MSRP-EHDA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY20-MSRP-CTA.pdf">https://cdmrp.army.mil/funding/pa/FY20-MSRP-CTA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY20-MSRP-IIRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-MSRP-IIRA.pdf</a>
<b>NEONATAL HEALTH (1)</b>						
74.	Innovations in Newborn Screening Interoperability (HHS/HSRA)	HRSA-20-134	This notice announces the opportunity to apply for funding under the Innovations in Newborn Screening Interoperability program (INBSI). The purpose of this program is to enhance data interoperability in the newborn screening (NBS) system. The recipient will accomplish this by serving as a national leader and resource on health information data interoperability and providing technical assistance, training, and education in data interoperability to state NBS programs. Interoperability is defined as the ability of different information systems, devices, and applications ('systems') to access, exchange, integrate, and cooperatively use data in a coordinated manner, within and across organizational, regional, and national boundaries, to provide timely and seamless portability of information and optimize the health of individuals and populations globally.	Proposal Due: 7/1/20	Up to \$1.3 million, for up to 3 years	<a href="https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=2c5fed9e-b33e-4232-bcce-1c85971cc33e">https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=2c5fed9e-b33e-4232-bcce-1c85971cc33e</a>



NEPHROLOGY & UROLOGY (2)					
75.	Coordinating Unit to Support the Kidney, Urology and Hematology (KUH) Innovative Science Accelerator Program (ISAC-CU) (U24 Clinical Trial Not Allowed) (NIH)	RFA-DK-20-010	The purpose of this FOA is to establish a Coordinating Unit to support the KUH Innovative Science Accelerator (ISAC-CU) Program. The ISAC-CU will administer a collaborative funding program intended to “seed” high-impact science of interest to the KUH research community. NIDDK intends to initiate the Innovative Science Accelerator (ISAC) Program, whose goals are to provide: 1. Seed funding, through a highly flexible funding process, for projects targeting discovery and exceptionally innovative, disruptive research in areas of science of interest and value to the KUH research communities; and 2. A platform for researchers funded through the program to exchange ideas and resources to enable collaboration and accelerate innovation. Based on these two goals, the ISAC Program will have two components: 1) a funding program and 2) a collaboration program.	Letter of Intent Due: 7/4/20  Proposal Due: 8/4/20	Up to \$1.15 million per year, for up to 5 year  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-010.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-010.html#_Section_II_Award_1</a>
76.	Pre-Announcement Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1 - Clinical Trial Not Allowed) (NIH)	NOT-DK-20-024	The National Institute of Diabetes and Digestive and Kidney Diseases intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to invite applications for Institutional Network Awards for Research Training (U2C/TL1). The purpose of these awards is to cultivate a highly integrated cohort of trainees and early career investigators and to develop career development resources in order to accelerate kidney, urologic, and hematologic research. To maximize integration and promote a true trainee community, institutions are invited to submit a single, unified U2C/TL1 application to engage, recruit, prepare, and sustain the next generation of kidney, urology, and hematology researchers. Applications covering a single metropolitan area are strongly encouraged. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.	Estimated Post Date: Spring 2020  Estimated Proposal Due Date: Fall 2020	Dependent upon proposal  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326711">https://www.grants.gov/web/grants/view-opportunity.html?opId=326711</a>

<b>ORGAN TRANSPLANTATION (1)</b>						
77.	Clinical Trials in Organ Transplantation in Children and Adults (CTOT-CA) (U01 Clinical Trial Optional) (NIH)	RFA-AI-20-029	The purpose of this FOA is to solicit applications to participate in a clinical studies program to improve the long-term outcome of adult and pediatric transplant recipients (thoracic organ, abdominal organ, vascular composite tissue, and cellular replacement). The Clinical Trials in Organ Transplantation in Children and Adults (CTOT-CA) program will support cooperative, multi-institutional consortia for the conduct of interventional trials (Phase 1, 2, or 3) or observational clinical studies in organ, vascularized composite tissue, or cellular replacement allotransplantation. Each applicant institution must represent a consortium of 2 or more clinical sites. Each clinical study must include associated mechanistic studies that focus on immune-mediated processes that are relevant to the proposed clinical study. The goals of this research will be to further our understanding of and ultimately reduce immune- and infection-mediated morbidity and mortality of allotransplantation.	Letter of Intent Due: 9/9/20  Proposal Due: 10/9/20	Dependent upon proposal, for up to 7 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-029.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-029.html#_Section_II_Award_1</a>
<b>PARKINSON'S DISEASE (3)</b>						
78.	Pre-Announcement NINDS Exploratory Grant Program in Parkinson's Disease Research (P20- Clinical Trial Optional) (P20 Clinical Trial Optional) (NIH)	NOT-NS-20-058	The National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a FOA to solicit applications for an Exploratory Grant Program in Parkinson's Disease Research. This initiative will request Exploratory Grant applications for the planning and initiation of collaborative efforts to advance Parkinson's Disease (PD) research. The goal of this program is to formalize new interdisciplinary teams to address critical gaps in PD research and establish a foundation of research discovery leading directly to an NINDS Morris K. Udall Center of Excellence for PD Research (P50) application. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in Summer 2020 with an expected application due date in Autumn 2020. This FOA will utilize the Exploratory Grant (P20) activity code. Details of the planned FOA are provided below.	Estimated Post Date: Spring 2020  Estimated Proposal Due Date: Fall 2020	Up to \$300,000 for award, for 1 year	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326708">https://www.grants.gov/web/grants/view-opportunity.html?opId=326708</a>

79.	Pre-Announcement NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional) (NIH)	NOT-NS-20-057	<p style="text-align: center;"><b>PARKINSON'S DISEASE</b></p> <p>The National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a FOA to solicit applications for the Morris K. Udall Centers of Excellence for Parkinson's Disease Research program. The overarching goal of this program is to establish a network of specialized Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson's disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Udall Centers also serve as local resources by providing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.</p>	Estimated Post Date: Spring 2020  Estimated Proposal Due Date: Fall 2020	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326714">https://www.grants.gov/web/grants/view-opportunity.html?opId=326714</a>
80.	FY20 Neurotoxin Exposure Treatment Parkinson's (NETP) (DoD/CDMRP)	W81XW H-20-NETP-EIRA; IIRA; SIA	The NETP Program invests in scientific research to better understand and treat the neuro- degenerative effects of PD associated with military deployment and environmental and/or occupational exposures. Research into military service-related risk factors is critical for past, present, and future Service members who may be affected by PD. Three different funding mechanisms are available.	Pre-Application Due: 8/18/20  Proposal Due: 9/16/20	Up to \$3 million, for up to 4 years	<a href="https://cdmrp.army.mil/funding/pa/FY20-NETP-EIRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-NETP-EIRA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY20-NETP-IIRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-NETP-IIRA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY20-NETP-SIA.pdf">https://cdmrp.army.mil/funding/pa/FY20-NETP-SIA.pdf</a>
<b>POPULATION HEALTH (3)</b>						
81.	Advancing the Centers of Excellence in Newcomer Health (CDC)	CDC-RFA-CK20-2002	This funding opportunity will advance the Centers of Excellence in Refugee Health to the Centers of Excellence in Newcomer Health to improve newcomer health outcomes, increase healthcare provider capacity, and to increase the number of newcomer related policy decisions that are based on evidence. The Centers of Excellence in Refugee Health (2015-2020) developed a secure data repository of health information of recently arrived newcomers, assisted CDC in the revision of health screening guidelines for these populations, and created an online tool to assist clinicians with the CDC health screening guidelines.	Proposal Due: 6/9/20	Up to \$1,000,000 per year for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=324431">https://www.grants.gov/web/grants/view-opportunity.html?opId=324431</a>  (See Related Documents Tab for Full Announcement)

82.	Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) (NIH)	PA-20-172	<p style="text-align: center;"><b>POPULATION HEALTH</b></p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.</p>	<p>Letter of Intent Due: 9/4/20, 1/4/21</p> <p>Proposal Due: 10/5/20, 2/5/20</p>	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-172.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-172.html#_Section_II._Award_1</a>
83.	Preventing Adverse Childhood Experiences Data to Action (CDC)	CDC-RFA-CE20-2006	<p>CDC announces a NOFO for Preventing Adverse Childhood Experiences: Data to Action (PACE:D2A), a cooperative agreement designed to address state-specific needs related to the prevention of adverse childhood experiences (ACEs). The two primary goals of this NOFO are 1) to build a state-level surveillance infrastructure that ensures the capacity to collect, analyze, and use ACE data to inform statewide ACE prevention activities; and 2) to support the implementation of data-driven, comprehensive, evidence-based ACE primary prevention strategies; and provide technical support to states in these efforts. This NOFO has three required foci to support these goals – 1) enhance or build the infrastructure for the state-level collection, analysis, and application of ACE-related surveillance data that can be used to inform and tailor ACE prevention activities, 2) implement strategies based on the best available evidence to prevent ACEs, and 3) conduct data to action activities to continue to assess state-wide surveillance and primary prevention needs and make needed modifications. The work of these foci, and the infrastructure and expertise exerted to accomplish that work, should be interdependent and should be planned and implemented as part of a comprehensive and coordinated ACE prevention dynamic system that reflects the 10 Essential Public Health Services promoted by CDC.</p>	<p>Letter of Intent Due: 5/22/20</p> <p>Proposal Due: 7/13/20</p>	Up to \$500,000 per year, for up to 3 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=324859">https://www.grants.gov/web/grants/view-opportunity.html?opId=324859</a>  (See Related Documents Tab for Full Announcement)

POST TRAUMATIC STRESS DISORDER (1)						
84.	Posttraumatic Stress Disorder-Drug Treatment (PTSD-DT) Adaptive Platform Trial (APT) (DoD/MTEC)	MTEC 20-11-PTSD-DT	<p>This solicitation, issued by the MTEC Consortium Manager (CM), Advanced Technology International (ATI), represents a Request for Project Proposals (RPP) for MTEC support of the DOD US Army Medical Materiel Development Activity (USAMMDA). Strategic oversight for the award(s) supported by this RPP will be provided USAMMDA's Warfighter Brain Health Project Management Office (WBH PMO). This RPP aims to support the development and maintenance of clinical trial infrastructure for the simultaneous and sequential testing of drug interventions to treat post-traumatic stress disorder (PTSD) in an adaptive platform trial (APT) design. The requirement for this RPP includes three focus areas. Offerors are not limited to a single proposal submission. It is expected that MTEC will make up to 3 awards - a single award for each focus area. It is possible that a single Offeror could receive an award for more than one Focus Area. Focus areas include:</p> <ul style="list-style-type: none"> <li>• <b>Focus Area #1 (Statistical Modeling):</b> Trial design, simulation, initiation, and execution, including drafting of key documents (e.g., statistical sections of Master Protocol, Statistical Analysis Plan, Operational Plan).</li> <li>• <b>Focus Area #2 (Drug Selection):</b> Operationalization and execution of a drug selection process for initial and continual selection of interventions to be tested in the APT.</li> <li>• <b>Focus Area #3 (Clinical and Clinical Operations):</b> Completion of the APT design, development of clinical trial infrastructure, and execution of the APT.</li> </ul>	Proposal Due: 5/21/20	Up to \$25.5 million, for up to 5 years  Dependent upon award mechanism	<a href="https://www.mtec-sc.org/wp-content/uploads/2020/04/20-11-PTSD-DT-RPP.pdf">https://www.mtec-sc.org/wp-content/uploads/2020/04/20-11-PTSD-DT-RPP.pdf</a>

			<b>REMOTE HEALTHCARE DELIVERY &amp; TELEMEDICINE (3)</b>			
85.	Pre-Announcement Rural Health Network Development Planning Program (HHS/HSRA)	HRSA-21-021	The purpose of the Network Planning program is to assist in the development of an integrated health care network, specifically network participants who do not have a history of formal collaborative efforts in order to: (i) achieve efficiencies; (ii) expand access to, coordinate, and improve the quality of essential health care services; and (iii) strengthen the rural health care system as a whole. A rural health network is defined as an organizational arrangement among at least three separately owned regional or local health care providers that come together to develop strategies for improving health services delivery systems in a community. Health care networks can be an effective strategy to help smaller rural health care providers and health care service organizations align resources and strategies, achieve economies of scale and efficiencies, and address challenges more effectively as a group than as single providers.	Estimated Post Date: 8/18/20  Estimated Proposal Due Date: 11/16/20	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326598">https://www.grants.gov/web/grants/view-opportunity.html?opId=326598</a>
86.	Pre-Announcement Rural Health Care Services Outreach Program (HHS/HSRA)	HRSA-21-027	The Outreach Program is a community-based grant program aimed towards promoting rural health care services by enhancing health care delivery in rural communities. Outreach projects focus on the improvement of access to services, strategies for adapting to changes in the health care environment, and overall enrichment of the respective community's health. Through a consortia of local health care and social service providers, rural communities can develop innovative approaches to challenges related to their specific health needs. Furthermore, the program creates an opportunity to address the key clinical priorities of HHS: serious mental illness, substance abuse, and childhood obesity. The overarching goals for the Outreach Program are to: Expand the delivery of health care services to include new and enhanced services exclusively in rural communities; Deliver health care services through a strong consortium, in which every consortium member organization is actively involved and engaged in the planning and delivery of services;	Estimated Post Date: 9/29/20  Estimated Proposal Due Date: 12/1/20	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326599">https://www.grants.gov/web/grants/view-opportunity.html?opId=326599</a>
87.	Distance Learning and Telemedicine Grants (USDA)	RUS-20-02-DLT	Authorized by 7 U.S.C. 950aaa, the DLT Program provides financial assistance to enable and improve distance learning and telemedicine services in rural areas. DLT grant funds support the use of telecommunications-enabled information, audio and video equipment, and related advanced technologies by students, teachers, medical professionals, and rural residents. These grants are intended to increase rural access to education, training, and health care resources that are otherwise unavailable or limited in scope.	Proposal Due: 7/13/20	Dependent upon proposal	<a href="https://www.rd.usda.gov/sites/default/files/USDARUS2020_DLT_FOAR2CARE_SActFunding_04142020.pdf">https://www.rd.usda.gov/sites/default/files/USDARUS2020_DLT_FOAR2CARE_SActFunding_04142020.pdf</a>



<b>REPRODUCTIVE HEALTH (1)</b>						
88.	Pregnancy Risk Assessment Monitoring System (PRAMS) (CDC)	RFA-DP-21-001	The activities in the NOFO will be conducted under three components of funding: <i>Component A:</i> To implement population-based surveillance on selected maternal behaviors and experiences that occur prior to, during, and shortly after pregnancy, including emerging issues, among women with a recent live birth in up to 53 vital records jurisdictions. <i>Component B:</i> Surveillance - among women with a recent live birth in up to 2 federally recognized American Indian Tribes, Alaska Native Villages, or Urban Indian Organizations <i>Component C:</i> To implement population-based surveillance on selected maternal behaviors and experiences that occur prior to, during, and shortly after pregnancy among women who recently experienced a stillbirth	Letter of Intent Due: 6/8/20  Proposal Due: 7/7/20	Up to \$8 million, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=325354">https://www.grants.gov/web/grants/view-opportunity.html?opId=325354</a>  (See Related Documents Tab for Full Announcement)
<b>SBIR/STTR (4)</b>						
89.	Small Business Innovation Research Program (SBIR) (NSF)	20-527; 528 (Phase I)  20-545; 546 (Phase II)	The NSF SBIR/STRR program focuses on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental research, the NSF SBIR program supports startups and small businesses in the creation of deep technologies, getting discoveries out of the lab and into the market. The NSF SBIR Program funds research and development. The program is designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development.	Proposal Due: 6/4/20, 9/3/20, 12/3/20	Up to \$256,000, for up to 1 year for Phase I  Up to \$1 million, for up to 2 years for Phase II	<a href="https://www.nsf.gov/pubs/2020/nsf20527/nsf20527.htm">https://www.nsf.gov/pubs/2020/nsf20527/nsf20527.htm</a>  <a href="https://www.nsf.gov/pubs/2020/nsf20545/nsf20545.htm">https://www.nsf.gov/pubs/2020/nsf20545/nsf20545.htm</a>  <a href="https://www.nsf.gov/pubs/2020/nsf20528/nsf20528.htm">https://www.nsf.gov/pubs/2020/nsf20528/nsf20528.htm</a>  <a href="https://www.nsf.gov/pubs/2020/nsf20546/nsf20546.htm">https://www.nsf.gov/pubs/2020/nsf20546/nsf20546.htm</a>
90.	Development of Fertility Regulation Methods by Small Business (R43/R44 Clinical Trial Optional) (NIH)	RFA-HD-21-007	The purpose of this FOA is to invite SBIR applications to support and facilitate the development of new and/or improved non-hormonal contraceptive, including contraceptives with anti-infective properties, products for men and women. Projects must be focused on the development of new and/or improved non-hormonal contraceptive products, or novel assay platforms that facilitate and support a single contraceptive, including a multipurpose prevention technology related product. Any proposed product must have characteristics consistent with the development of a safe and effective contraceptive acceptable to women or men. All applications for Phase II programs focused on contraceptive product development must include in vivo product testing.	Letter of Intent Due: 6/30/20  Proposal Due: 7/30/20	Up to \$225,000 for up to 6 months for Phase I  Up to \$1.5 million for up to 2 years for Phase II	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-21-007.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-21-007.html#_Section_II_Award_1</a>

91.	Pre-Announcement PHS 2020 Omnibus Solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications (NIH)	NOT-OD-20-099	<p style="text-align: center;"><b>SBIR/STTR</b></p> <p>This Notice is to inform the eligible United States small business concerns of the reissuance of the Omnibus Solicitations of the NIH, CDC and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications. When reissued, these FOAs will continue to utilize the R41/R42 and R43/44 grant mechanisms. Modifications to these FOAs will be the inclusion of new and revised research priorities. Office of Orphan Products Development (OOPD/FDA). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects.</p>	<p>Estimated Post Date: Spring 2020</p> <p>Estimated Proposal Due Date: Summer 2020</p>	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326712">https://www.grants.gov/web/grants/view-opportunity.html?opId=326712</a>
92.	Federal and State Technology (FAST) Partnership Program (SBA)	FAST-2020-R-0014	<p>The Federal and State Technology (FAST) Partnership Program provides one-year funding to organizations to execute state/regional programs that increase the number of SBIR/STTR proposals leading to an increase in the number of SBIR/STTR awards. The mission of SBA's Office of Innovation &amp; Technology, which bears responsibility for administering the FAST Program, is to strengthen the technological competitiveness of small businesses across the country through coordination and oversight of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. The primary mission of the FAST program is to help underrepresented entrepreneurs successfully compete for SBIR/STTR awards.</p>	Proposal Due: 6/19/20	Up to \$125,000 for 1 year	<a href="https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=73403">https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=73403</a>

<b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT (9)</b>						
93.	Inclusion across the Nation of Communities of Learners of Underrepresented Discoverers in Engineering and Science (NSF)	20-569	The NSF INCLUDES Big Idea is a comprehensive national initiative to enhance U.S. leadership in science, technology, engineering, and mathematics (STEM) discoveries and innovations focused on NSF's commitment to diversity, inclusion, and broadening participation in these fields. The vision of NSF INCLUDES is to catalyze the STEM enterprise to work collaboratively for inclusive change, resulting in a STEM workforce that reflects the population of the Nation. More specifically, NSF INCLUDES seeks to improve collaborative efforts aimed at enhancing the preparation, increasing the participation, and ensuring the contributions of individuals from groups that have been historically underrepresented and underserved in the STEM enterprise such as African Americans, Alaska Natives, Hispanics, Native Americans, Native Hawaiians, Native Pacific Islanders, persons with disabilities, persons from economically disadvantaged backgrounds, and women and girls. Significant advancement in the inclusion of underrepresented groups in STEM will result in a new generation of STEM talent and leadership to secure our nation's future and long-term economic competitiveness.	Letter of Intent Due: 10/4/20  Proposal Due: 1/26/21	Up to \$2 million per year, for up to 5 years	<a href="https://www.nsf.gov/pubs/2020/nsf20569/nsf20569.htm">https://www.nsf.gov/pubs/2020/nsf20569/nsf20569.htm</a>
94.	FY20 Funding Opportunity Announcement (FOA) for the Department of Navy (DoN) Science, Technology, Engineering & Mathematics (STEM), Education and Workforce Program administered by the Office of Naval Research (DoD/ONR)	N00014-20-S-F005	ONR seeks a broad range of applications for augmenting existing or developing innovative solutions that directly maintain, or cultivate a diverse, world-class STEM workforce in order to maintain the U.S. Navy and Marine Corps' technological superiority. The goal of any proposed effort must provide solutions that will establish and maintain pathways of diverse U.S. citizens who are interested in uniformed or civilian DoN STEM workforce opportunities. As the capacity of the DoN Science and Technology (S&T) workforce is interconnected with the basic research enterprise and STEM education system, ONR recognizes the need to support efforts that can jointly improve STEM student outcomes and align educational efforts with Naval S&T current and future workforce needs. This announcement explicitly encourages projects that improve the capacity of education systems and communities to create impactful STEM educational experiences for students and workers. Submissions are encouraged to consider including active learning approaches and incorporating 21st century skill development. Projects must aim to increase student and worker engagement in STEM and enhance people with needed Naval STEM capabilities.	White Paper Due: 6/12/20  Proposal Due: 8/28/20	Up to \$250,000 per year, for up to 3 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326757">https://www.grants.gov/web/grants/view-opportunity.html?opId=326757</a>  (See Related Documents Tab for Full Announcement)

95.	Discovery Research Pre K-12 (NSF)	20-572	<p><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>The Discovery Research PreK-12 program (DRK-12) seeks to significantly enhance the learning and teaching of science, technology, engineering, mathematics and computer science (STEM) by preK-12 students and teachers, through research and development of STEM education innovations and approaches. Projects in the DRK-12 program build on fundamental research in STEM education and prior research and development efforts that provide theoretical and empirical justification for proposed projects. Projects should result in research-informed and field-tested outcomes and products that inform teaching and learning. Teachers and students who participate in DRK-12 studies are expected to enhance their understanding and use of STEM content, practices and skills.</p>	Proposal Due: 10/7/20	Up to \$5 million, for up to 6 years	<p><a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=500047">https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=500047</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=326833">https://www.grants.gov/web/grants/view-opportunity.html?oppId=326833</a></p>
96.	Notice of Special Interest: NCCIH Administrative Supplements to NCATS CTSA Programs for Scholars Pursuing Complementary Health Research Career Development (NIH)	NOT-AT-20-010 PA-18-591	<p>The purpose of the National Center for Complementary and Integrative Health (NCCIH) Administrative Supplement to the National Center for Advancing Translational Sciences (NCATS)-supported Clinical and Translational Science Awards (CTSA) program is to develop a pipeline of qualified clinician-scientist investigators with complementary and integrative health degrees and expertise conducting clinical or translational research on complementary clinical interventions for NCCIH high-priority research topics. This Notice of Special Interest (NOSI) will support additional scholar slots to those KL2 grants currently approved under the CTSA Program. Applications for this initiative must be submitted using the following opportunity: PA-19-591, or its subsequent reissued equivalent.</p>	Proposal Due: 10/1/20	Dependent upon proposal, for up to 4 years	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-010.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-010.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html</a></p>

97.	Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed) (NIH)	PA-20-171; 173; 174	<p align="center"><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.</p>	Proposal Due: 6/10/20, 10/10/20, 2/10/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-171.html#_Section_II._Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-171.html#_Section_II._Award_2</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-173.html#_Section_II._Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-173.html#_Section_II._Award_2</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-174.html#_Section_II._Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-174.html#_Section_II._Award_2</a>
98.	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required, Independent Clinical Trial Not Allowed, Independent Basic Experimental Studies with Humans Required) (NIH)	PA-20-187; 188; 189	<p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.</p>	Proposal Due: 6/12/20, 10/12/20, 2/12/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-187.html#_Section_II._Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-187.html#_Section_II._Award_2</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-188.html#_Section_II._Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-188.html#_Section_II._Award_2</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-189.html#_Section_II._Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-189.html#_Section_II._Award_2</a>

99.	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed, Independent Basic Experimental Studies with Humans Required, Independent Clinical Trial Required) (NIH)	PA-20-186; 192; 193	<p align="center"><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. For the purposes of the K24 award, Patient-Oriented Research is defined as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. This area of research includes: (1) mechanisms of human disease; (2) therapeutic interventions; (3) clinical trials, and; (4) the development of new technologies. Excluded from this definition are in vitro studies that utilize human tissues but do not deal directly with patients.</p>	Proposal Due: 6/12/20, 10/12/20, 2/12/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-186.html#_SectionII.Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-186.html#_SectionII.Award_2</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-192.html#_SectionII.Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-192.html#_SectionII.Award_2</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-193.html#_SectionII.Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-193.html#_SectionII.Award_2</a>
100.	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required, Independent Clinical Trial Not Allowed, Independent Basic Experimental Studies with Humans Required)	PA-20-176; 190; 191	<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.</p>	Proposal Due: 6/12/20, 10/12/20, 2/12/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-176.html#_SectionII.Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-176.html#_SectionII.Award_2</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-190.html#_SectionII.Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-190.html#_SectionII.Award_2</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-191.html#_SectionII.Award_2">https://grants.nih.gov/grants/guide/pa-files/PA-20-191.html#_SectionII.Award_2</a>



101.	Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional) (NIH)	PAR-20-167	<p><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program.</p>	Proposal Due: 8/28/20	Up to \$499,000 per year, for up to 7 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-167.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-167.html#_Section_II_Award_1</a>
			<p><b>TRANSLATIONAL RESEARCH &amp; PRODUCT DEVELOPMENT (3)</b></p>			
102.	IDEA Program Infrastructure for Clinical and Translational Research (IDEA-CTR) (U54 - Clinical Trial Optional) (NIH)	PAR-20-175	<p>The purpose of the IDEA-CTR initiative is to expand the capacity for clinical and translational research in IDEA-eligible states/jurisdictions and to enhance the competitiveness of the investigators to obtain extramural funding for clinical and translational research. This FOA provides cooperative agreement support for statewide and/or interstate regional networks to achieve the following objectives: (1) to support the development and/or enhancement of infrastructure and human resources required to address clinical and translational research needs in IDEA-eligible states/jurisdictions, (2) to strengthen clinical and translational research that addresses the broad spectrum of health challenges faced by populations in IDEA-eligible states/jurisdictions, and (3) to foster and coordinate collaboration in clinical and translational research within an IDEA-CTR network and with other institutions.</p>	Letter of Intent Due: 9/7/20  Proposal Due: 10/7/20	Up to \$4 million per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-175.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-175.html#_Section_II_Award_1</a>

103.	Biological Technologies (DoD/DARPA)	HR00112 0S0044	<p style="text-align: center;"><b>TRANSLATIONAL RESEARCH &amp; PRODUCT DEVELOPMENT</b></p> <p>The mission of BTO is to foster, demonstrate, and transition breakthrough research, discoveries, and applications that integrate biology, engineering, computer science, mathematics, and the physical sciences. BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, microbes as production platforms, and deep exploration of changing ecologies and environments on U.S. capabilities and resilience. BTO is interested in submissions including, but not limited to the following areas: (1) Discovering and leveraging novel findings from biotechnology, biochemistry, molecular biology, neuroscience, psychology, cognitive science, and related disciplines to advance treatment and resilience in neurological health, transformative neural processing, and optimize human performance (2) Understanding and improving interfaces between the biological and physical world to enable seamless hybrid systems and revolutionary new human-machine interfaces (3) Designing novel materials, sensors, or processes that mimic or are inspired by biological systems.</p>	Proposals Accepted on a Rolling Basis until 4/22/21	Dependent upon Proposal	<a href="https://beta.sam.gov/opp/4efd37762ed0475d871af927279f010d/view">https://beta.sam.gov/opp/4efd37762ed0475d871af927279f010d/view</a>
104.	2020 Office of Naval Research (ONR) Global Research Opportunity: Global-X Challenge (DoD/ONR)	N00014-20-S-SN14	The purpose of this Global-X Challenge is to discover, disrupt, and ultimately provide a catalyst for later development and delivery of revolutionary capabilities to the U.S. Navy and Marine Corps, the commercial marketplace, and the public. The expected outcomes of this Global-X Challenge are promising revolutionary concepts whose technology maturity may be accelerated under separate agile follow-on technology development efforts. Challenge areas include: 1) Tailored material and manufacturing in areas such as machine learning, digital manufacturing and synthetic biology, 2) Multifunctional Maritime Films for Persistent and Survivable Platforms and Warfighters focused on technical disciplines including but not limited to microbiology and virology, 3) Object Detection and Identification in Any Medium.	White Paper Due: 5/25/20, Proposal Due: 7/13/20	Up to \$750,000, for up to 9 months	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326462">https://www.grants.gov/web/grants/view-opportunity.html?opId=326462</a>  (See Related Documents for Full Announcement)

<b>TRAUMATIC BRAIN INJURY (1)</b>							
105.	Noninvasive mTBI Tool RFI (DoD/USU)	HU00012 OR0047	USU is issuing this Request for Information (RFI) to survey available and/or emerging technologies that have the potential to address the following areas of interest in the detection and management of mTBI: 1) Utility of the non-invasive technologies, individually or in combination, as initial diagnostic and/or screening tool(s) for individuals who have been exposed to events associated with mTBI (i.e. individuals who have been exposed to scenarios associated with a risk of mTBI, but in whom the diagnosis has not yet been made). The technology or technologies should be compared against current standard(s) of care. 2) Ability of available and/or emerging biomedical non-invasive technologies, individually or in combination, to provide prognostic information that can among other things, predict return to activity/duty time for those who have been diagnosed with concussion/mTBI when compared to current standard(s) of care/return to activity protocols. 3) Utility of the non-invasive technologies, individually or in combination, to serve as tools by which inclusion and or exclusion criteria can be determined for entry of individuals into clinical studies of candidate therapeutics in the management of mTBI. Comparative assessment of the technology or technologies should be against current clinical standards (treatment of functional deficits and symptoms related to mTBI will be prioritized).	Response Due: 7/27/20	This RFI is issued solely for information and planning purposes and does not constitute a solicitation or issuance thereof.	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326511">https://www.grants.gov/web/grants/view-opportunity.html?opId=326511</a>	(See Related Documents Tab for Full Announcement)
<b>OTHER (5)</b>							
106.	Pre-Announcement NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens (U01) Clinical Trials Not Allowed (FDA)	FOR-FD-20-006	This Funding Opportunity Announcement (FOA) issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), builds upon the National Antimicrobial Resistance Monitoring System (NARMS) which was initiated in 1996 as one of the key activities in a national action plan to combat antibiotic resistance threats. The purpose of this FOA is to protect and promote public health by enhancing, strengthening and sustaining antibiotic resistance surveillance in retail food specimens within the NARMS program. The NARMS cooperative agreements is intended to improve the detection of antibiotic resistance among bacteria in food commodities, as well as expand to new sites to expand the scope of sampling. Measurable outcomes of the program will be in alignment with the NARMS Objectives.	Estimated Post Date: Spring 2020  Estimated Proposal Due Date: Fall 2020	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=324297">https://www.grants.gov/web/grants/view-opportunity.html?opId=324297</a>	

107.	Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) (NIH)	PA-20-200	<p style="text-align: center;"><b>OTHER</b></p> <p>The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).</p>	<p>Proposal Due: 6/16/20, 10/16/20, 2/16/21</p>	Up to \$50,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-200.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-200.html#_Section_II_Award_1</a>
108.	Targeted Needs to Achieve SPARC Program Goals (NIH)	OTA-20-004	This funding opportunity will allow the SPARC program to evaluate and potentially fund new projects across all program components to address specific program gaps and Funding Priorities. SPARC Priorities will be developed and updated by the NIH SPARC management team based on developing program needs. Priorities may be influenced by SPARC-funded investigators, other investigators, broader stakeholders, and SPARC Subject Matter Experts. Current priority: Interoperable, extensible, and personalizable simulations on the o2S2PARC platform (link is external) to inform bioelectronic medicine development, with particular focus on diseases and conditions that impact the stomach, colon, lungs, heart, or lower urinary tract.	<p>Concept Letter Due: 6/1/20</p> <p>Proposal Due: 7/1/20</p>	Up to \$5 million per year	<a href="https://commonfund.nih.gov/sites/default/files/SPARC_Targeted_Needs_FOA_19apr2020_508.pdf">https://commonfund.nih.gov/sites/default/files/SPARC_Targeted_Needs_FOA_19apr2020_508.pdf</a>
109.	PCORI Funding Announcement: Implementation of Effective Shared Decision-Making (SDM) Approaches in Practice Settings (PCORI)	N/A	This PCORI Funding Announcement (PFA) is intended to promote the targeted implementation and systematic uptake of shared decision making (SDM) in healthcare settings, in line with PCORI's goal of supporting patients in making informed decisions about their care. For this PFA, PCORI defines an SDM strategy as an intervention or approach that draws on and presents evidence to inform patients of available treatment options and their risks and benefits, and either engages patients in a decision-making process with their clinician or promotes their ability to engage in such a process. This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision-making strategies that address existing barriers and obstacles to uptake and maintenance of shared decision making. The SDM strategy must have demonstrated effectiveness on patient, caregiver, or healthcare provider decision making using widely accepted metrics; the corresponding implementation approach must have potential for use and scalability beyond the targeted implementation setting.	<p>Letter of Intent Due: 6/18/20</p> <p>Proposal Due: 8/31/20</p>	Up to \$1.5 million, for up to 3 years	<a href="https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-Shared-Decision-Making-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-Shared-Decision-Making-PFA.pdf</a>

110.	Limited PCORI Funding Announcement: Implementation of PCORI-Funded Patient-Centered Outcomes Research Results – Cycle 2 2020 (PCORI)	N/a	<p style="text-align: center;"><b>OTHER</b></p> <p>The intent of this limited PFA is to move evidence developed with PCORI research funding toward practical use in improving health care and health outcomes. PCORI will fund projects that aim to implement patient-centered clinical comparative effectiveness research (CER) results obtained from PCORI-funded studies in decision-making settings, and, in selected cases, projects that focus on the dissemination of these findings. This limited PFA gives PCORI investigators the opportunity—following the generation of results from their PCORI-funded research award—to propose the next step(s) for making their research results more useful, actionable, accessible, and available to targeted end-users of these findings.</p>	<p>Letter of Intent Due: 6/18/20</p> <p>Proposal Due: 8/31/20</p>	<p>Up to \$1 million, for up to 3 years</p>	<p><a href="https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-Implementation-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-Implementation-PFA.pdf</a></p>
------	--	-----	--	---	---	--